Cynthia L. Comella | Psychiatrist.com

Original Research

Long-Term Valbenazine for Tardive Dyskinesia

Valbenazine, a VMAT2 inhibitor, is approved for the treatment of tardive dyskinesia. However, its long-term safety and efficacy have not been reported. This extension of the KINECT 3 study...

The Clinician’s Tardive Inventory

Original Research

The Clinician’s Tardive Inventory

Accurately identifying the severity and functional impact of tardive dyskinesia is essential. This report describes a new instrument, the Clinician’s Tardive Inventory, which aims to address shortcomings of existing...